**Core tip:** Leukemia stem cell (LSC) directed therapy targets: (1) Cell surface markers expressed on LSC: CD33, CD44, CD123, CD47, *etc*.; (2) Crucial pathways for maintenance of their stemness: NF-κB, PI3K/AKT/mTOR and bcl-2; and (3) Interactions between LSC in the bone marrow niche: LSC mobilization with granulocyte-colony stimulating factor and inhibition of LSC homing to the bone marrow by interrupting the C-X-C chemokine receptor type 4-CXCL12 and VCAM-VLA4 axis.

INTRODUCTION
============

Despite extensive research efforts in myeloid malignancies, minimal progress has been made in introducing new effective treatment strategies for acute myeloid leukemia (AML) since the introduction of the anthracycline-cytarabine combination chemotherapy regimens (known as 7 + 3) more than 40 years ago\[[@B1]\]. Despite achieving complete remission (CR) with intensive induction chemotherapy in about 70% of patients with AML, relapse is frequent and the rate of 5-year disease free survival is only about 30%-40%. It has been long proposed that the high rate of relapse is due to the persistence of a rare subset of malignant cells that are not effectively eliminated by current treatment regimens, the so called leukemia stem cells (LSCs)\[[@B2]-[@B4]\]. LSC were first identified but tumor cells with stem cell-like behavior were later found to be also present in a variety of solid tumors\[[@B5]-[@B9]\]. LSC remain the best studied and characterized cancer stem cell (CSC) due to the easy accessibility of tumor tissue for (*i.e*., blood and bone marrow) and the availability of a number of cell surface markers that allow their prospective identification and isolation by flow cytometry followed by assays to examine their function both *in vitro* and *in vivo*\[[@B10]\]. This review will focus on the biology of LSC, the impact they have on current leukemia diagnosis and prognosis and treatment as well as future directions of leukemia therapy based on targeting LSC\[[@B6]\].

CSC *VS* CLONAL EVOLUTION THEORY
================================

It is now well understood that not only tumors from different patients but also cells within a single tumor are characterized by heterogeneity in terms of the morphology, cell surface markers, genetic variations and response to therapy\[[@B11]\]. Why there is significant variation in genetic and epigenetic abnormalities between different cells or locations within a tumor despite the clonal origin of all tumor cells, is a question that has puzzled researchers for decades. There are essentially two different explanations for this fundamental problem of cancer biology: The hierarchy or CSC model *vs* the stochastic or clonal evolution model\[[@B6]\]. In the stochastic model, all cells in a tumor have a similar biological function but are heterogeneous (*e.g*., expression of cell surface markers) because of clonal evolution resulting in small but entirely random/stochastic variations triggered by external and internal factors based on Darwinian principles. Importantly, all cells within the tumor have an equal sensitivity to both intrinsic (transcription factors and signaling pathways) and extrinsic (host factors, tumor microenvironment and immune response) factors\[[@B10]\]. In the cancer stem cell (CSC) model, a tumor follows the principles of normal, healthy tissue development with a stem cell at the top of the hierarchy, which gives rise to all other cells in the tumor. In this model only these rare population of CSCs are able to initiate tumor growth: They possess self-renewal capacity and can be isolated from the bulk non-tumorigenic population. Importantly, both models appreciate the existence of a CSC but differ in their assessment what cells within the tumor can be CSCs. In the stochastic model CSCs are created randomly and every cell has the potential to be a CSC, whereas in the CSC model only a subset of cancer cells has the potential to behave like a stem cell\[[@B11]\].

Whether the stochastic model or the CSC model best reflects tumorigenesis/leukemogenesis, has significant impact on how cancer/leukemia should be treated\[[@B10]\]. In the stochastic model, the cells within a tumor are relatively homogeneous in terms of genetic makeup and function and therapy can be uniformly directed at the bulk of tumor cells. However, per the CSC model, tumorigenic pathways might operate differently in CSCs compared with the bulk cells and therapy must specifically target the CSCs in order to be truly effective. Most of the current targeted therapies against leukemia and cancer focuses on inhibiting the molecular drivers found in all cancer cells but do not necessarily target CSCs\[[@B11]\].

BIOLOGY OF LSCS
===============

CSC characteristics
-------------------

The definition of a LSC is adapted from normal HSC: It is a cell that possesses the capacity to self-renew, proliferates and gives rise to leukemic blasts, which are morphologically homogeneous but biologically heterogeneous\[[@B12]\]. Apart from self-renewal potential, dormancy/quiescence and a protective stem cell niche are shared characteristics between HSCs and LSCs.

**Self-renewal capacity:** As the definition of CSCs is a functional definition, CSCs can thus only be defined experimentally by their ability to recapitulate the generation of a continuously growing tumor. Immunodeficient mice, such as the non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse and newer generations of xenograft models, are used to functionally define human hematopoietic stem and progenitor cells as well as LSCs\[[@B13]\]. Long-term repopulating cells, thought to be LSC are able to be successfully engrafted in these mice over prolonged periods as well as in secondary recipients\[[@B2],[@B14]\]. Bonnet et al\[[@B15]\] in the John Dick laboratory isolated subpopulations of cells from primary human AML bone marrow based on their immunophenotype and xenotransplanted them into NOD/SCID mice. It demonstrated that the CD34^+^CD38^-^ expressing sub-population of AML cells were capable of being serially transplanted in these immunodeficient mice\[[@B15],[@B16]\]. Reflecting the emphasis on functional assessment, these cells were named as SCID leukemia-initiating cells (SL-IC) and are considered the equivalent of LSC.

**Symmetrical *vs* asymmetrical cell division:** Similar to HSCs, LSCs have the ability to undergo symmetrical self-renewing cell division, generating identical daughter stem cells that retain self-renewal capacity (expansion), or an asymmetrical self-renewing cell division, resulting in one stem cell and one more differentiated progenitor cell (maintenance)\[[@B12],[@B17]-[@B19]\]. Normal stem cells are able to switch between symmetrical and asymmetrical division based on the demands of the tissue they are meant to maintain. During early embryogenesis normal stem cells undergo symmetrical cell division in order to expand the total pool of stem cells giving rise to tissues whereas in adult tissues stem cells give rise to mature cells though asymmetrical cell division\[[@B19],[@B20]\]. There is increasing amount of evidence that in CSCs this delicate balance seems to be disturbed in favor of symmetric cell division\[[@B19],[@B21],[@B22]\]. For example, CSCs isolated from ERBB2-expressing breast cancer have been demonstrated to prefer symmetric cell division compared to normal breast tissue stem cells\[[@B23]\]. Furthermore, the adenomatous polyposis coli tumor suppressor gene (*APC*) has been shown to paly a major role in regulating asymmetric cell division in drosophila and its mutational loss is suspected to lead to an expansion of CSCs by symmetric cell division\[[@B22],[@B24],[@B25]\].

**Stem cell quiescence and exhaustion:** Normal stem cells need to be quiescent to avoid exhaustion of a stem cell pool and to minimize the risk of oncogenic events\[[@B26]\]. In fact, stem cell exhaustion has been described as one reason for aging and as a consequence of the attempt of the body to prevent the development of cancer\[[@B27]\]. Aging leads to an accumulation of DNA damage in all cells of the body, including stem cells, which in turn leads to an increased risk of developing cancer. Aging stem cells are affected by sophisticated mechanisms cells have developed to suppress the development of cancer, mainly induction of senescence and apoptosis, which are mediated through telomere shortening and activation of tumor suppressor genes *p16* and *p53*\[[@B28]-[@B30]\]. The diminished ability of aging HSC to reconstitute the hematopoietic system is demonstrated by prolonged myelosuppression after cytotoxic chemotherapy in older patients as well as age of the stem cell donor being significantly associated with overall and disease-free survival after hematopoietic stem cell transplant\[[@B31],[@B32]\].

However, normal stem cells are also required to continuously replenish the cells that are lost in a tissue. In order to fulfill both purposes-avoid exhaustion as well as maintaining the cellular integrity of a tissue-stem cells undergo asymmetric cell divisions, which give rise to another stem cell as well as a rapidly dividing progenitor cells. These progenitor cells proliferate quickly for a limited amount of cell divisions and regenerate all cells in a tissue\[[@B33],[@B34]\].

Similarly, LSCs are quiescent, which explains the difficulties to eradicate LSCs with standard chemotherapies that preferentially target rapid proliferating cells\[[@B35]-[@B37]\].

**Key signaling pathways relevant for retaining stemness:** Similar signaling pathways involved in the control of self-renewal of HSCs are also key elements maintaining stemness in LSCs (Figure [1](#F1){ref-type="fig"}). Among many others, these pathways include PI3K/Akt/mTOR\[[@B38]\], Wnt/beta-catenin\[[@B39],[@B40]\], Hedgehog\[[@B41],[@B42]\], NF-kB\[[@B43],[@B44]\], Notch\[[@B45]\] and Bcl-2\[[@B46],[@B47]\]. Several drugs targeting these pathways are in different stages of preclinical and clinical development (Figure [1](#F1){ref-type="fig"}).
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**Stem cell niche:** The bone marrow niche is quintessential for normal HSC to maintain their quiescence but at the same time enable HSC to generate cells in the blood stream to meet the organism's needs\[[@B48]\]. The stem cell niche is formed by a complex network of different cells including vascular endothelial cells, perivascular mesenchymal cells, megakaryocytes, osteoblastic lineage cells, macrophages and nerve cells\[[@B49]-[@B53]\]. Dysregulation of the bone marrow niche plays an important role in preventing the detection of LSC by the immune system and protecting LSC from the effects of chemotherapy\[[@B48],[@B54]\]. Similar to normal HSCs, LSCs are retained in the marrow niche by interactions between CXCR4, on stem cells, and CXCL12 (SDF-1), on osteoblasts and mesenchymal cells in the bone marrow niche\[[@B55],[@B56]\]. Chemokine interactions through CXCL12 can lead to up-regulation of vascular cell adhesion molecule-1 (VCAM-1) and very late antigen-4 (VLA-4) expression, which further strengthen LSC retention in the marrow niche\[[@B57],[@B58]\] (Figure [1](#F1){ref-type="fig"}). The significance of the interaction between LSCs and the protective bone marrow niche is exemplified by the fact that elevated levels of CXCR4 and VLA-4 have been associated with poor response to chemotherapy and decreased survival\[[@B59]-[@B61]\]. Several therapeutic approaches attempt to break the dormancy of LSCs by induction of stem cell cycling with granulocyte-colony stimulating factor (G-CSF) and inhibition of the CXCR4-SDF-1 axis involved in LSC retention in the protective bone marrow niche\[[@B62],[@B63]\] (Figure [1](#F1){ref-type="fig"}).

Identification of LSCs by surface markers
-----------------------------------------

Recent studies have shown that LSCs may reside not only in CD34^+^CD38^-^, but also in CD34^+^CD38^+^ and CD34^-^ CD38^+^ compartments demonstrating the lack of a definitive phenotype for LSCs\[[@B64]-[@B66]\]. Several studies have shown that the CD34^+^CD38^+^ fraction has repopulating ability when immunosuppression is applied\[[@B18],[@B67],[@B68]\]. It was demonstrated that by treating mice with immunosuppressive antibodies, the CD34^+^CD38^+^ fraction of AML samples is able to initiate leukemia in immunodeficient mice\[[@B64]\]. Furthermore, by transplanting sorted fractions of primary *NPM*-mutated AML into immunodeficient mice, it was shown that approximately one-half of cases had LICs exclusively within the CD34^-^ fraction, whereas the CD34^+^ fraction contained normal multilineage hematopoietic repopulating cells\[[@B66]\]. Most of the remaining cases had LICs in both CD34^+^ and CD34^-^ fractions and when samples were sorted based on CD34 and CD38 expression, multiple fractions initiated leukemia in primary and secondary recipients (Table [1](#T1){ref-type="table"}).

###### 

Markers of leukemia stem cells

  **Cell surface** **markers**    **Patient samples used**                         **Mouse model used**                                             **Ref**.
  ------------------------------- ------------------------------------------------ ---------------------------------------------------------------- -----------------
  CD34^+^CD38^-^                  FAB M1, M4, M5                                   NOD/SCID                                                         \[15,16\]
  CD34^+^CD38^+^                  CN-AML, MLL-ENL                                  NOD/SCID + IVIG or anti-CD122                                    \[18,64,67,68\]
  CD34^-^CD38^+^                  AML with NPM1 mutation                           NOD/SCID β-2 microglobulin NOD/SCID IL2 receptor γ^−/−^ + IVIG   \[66\]
  CD34^+^CD123^+^                 FAB M1, M2, M4                                   NOD/SCID                                                         \[69\]
  CD34^+^CD38^-^CD96^+^           CK-AML, CBFB-MYH11, PML-RARA, AML1-ETO, FAB M4   Rag2^-/-^ IL2RG^-/-^                                             \[70\]
  CD34^+^CLL1^+^                  AMLs with FLT3-ITD                               NOD/SCID                                                         \[71\]
  TIM3^+^                         FAB M1, M2, M4                                   NOD/Rag1^-/-^ IL2RG^-/-^                                         \[72\]
  CD34^+^CD38^-^ CD33^+^CD13^+^   CN-AML, CBF-AML, MLL-ENL                         NOD/SCID                                                         \[73\]

FAB: French-American-British classification system; CN: Cytogenetically normal; CK: Cytogenetically complex; MLL-ENL: Mixed-lineage leukemia-eleven nineteen leukemia; NPM1: Nucleophosmin 1; CBFB-MYH11: Core binding factor beta unit-Myosin heavy chain 11; PML-RARA: Promyelocytic leukemia-retinoic acid receptor alpha; AML1-ETO: Acute myeloid leukemia 1 protein- eight twenty one; FLT3-ITD: Fms-like tyrosine kinase 3 Internal tandem duplication; NOD/SCID: Non-obese diabetic/severe combined immunodeficiency; Rag: Recombination activating gene; IL2RG: Interleukin 2 receptor subunit gamma.

Heterogeneity within the LSC population
---------------------------------------

Over the last years several groups have found a wide variety of other markers that appear to be expressed higher in LSCs than normal HSCs\[[@B14]\].

These include CD123, CD96, CLL-1, TIM3, CD33, CD13, CD44, CD47 and others\[[@B69]-[@B75]\] (Table [1](#T1){ref-type="table"}). In essence, these studies suggest that leukemogenic activity is not restricted to the CD34^+^CD38^-^ fraction and there is heterogeneity among patients in leukemogenic cell phenotype. Over the last years, there has been significant advancement in the understanding of the complexity and heterogeneity of human LSC. Several important observations have been made along the way of discovery.

**LSC heterogeneity within a patient:** First, there is heterogeneity of the stem cell population within the same patient as not all LSC have the same self-renewal capacity\[[@B10],[@B76]\]. Use of lentiviral gene marking to track the behavior of individual leukemia initiating cells following serial transplantation has revealed heterogeneity in their ability to repopulate secondary and tertiary recipients and this enabled researchers to classify long term (LT-LSC) and short term (ST-LSC) LSCs\[[@B76],[@B77]\]. LT-LSCs are defined by a long-termed persistence in xenotransplantion models given an extensive self-renewal capacity while ST-LSCs have a reduced self-renewal capacity and only a transient repopulation capability in xenotransplantation models.

**LSC heterogeneity based on the specific xenotransplantation model used:** The LSC phenotype depends on what mouse model is used for functional assessment of stem cell properties of human AML cells\[[@B14]\] (Table [1](#T1){ref-type="table"}). The bone marrow niche in mice differ from that of humans in terms of architecture, stromal cells, cytokines, growth factors, adhesion molecules and most importantly the immune cell composition, which potentially impairs growth of human HSC or LSC in the mouse bone marrow\[[@B78]\]. Normal HSCs and LSC are therefore more likely to be detected in more highly immunodeficient mice. As different xenotransplantation mouse models display different levels of immunodeficiency they are associated with different levels of engraftment of normal human HSCs and LSCs\[[@B6],[@B14]\]. In nude mice T cells are absent whereas in severe combined immunodeficiency mice (SCID mice) both B and T cells are inactivated. NOD/SCID mice, which harbor defects in T, B, and macrophage activity, support higher levels of human engraftment\[[@B14]\]. NOD/SCID gamma (NSG) mice have almost no murine immune system left as a complete null mutation in the gene encoding the interleukin 2-receptor gamma chain blocks NK cell differentiation\[[@B79]\]. Similarly, NK cells can be depleted by treating NOD/SCID mice with anti-CD122 antibodies\[[@B80]\]. In creating a supportive bone marrow niche for engraftment of human AML cells not only a suppression of the hosts immune system is essential but also a recreation of the cytokine environment supporting stem cell self-renewal and quiescence\[[@B14]\]. This has led to the development of mice models that express human cytokines like human SCF, GM-SCF, IL3 and TPO\[[@B13],[@B81]\].

**LSC heterogeneity between patients:** It has become increasingly evident that the LSC phenotype varies between patients based on the specific subtype of leukemia that they suffer from (Table [1](#T1){ref-type="table"}). As mentioned above, the majority of AML cells express CD34, however in AML cells carrying a mutation in NPM1 the CD34^+^ percentage is very low and LSC activity is exclusively restricted to the CD34^-^ population\[[@B66]\]. Furthermore, specific subtypes of AML (in particular less aggressive subtypes) are significantly more difficult to be engrafted as they may have low progenitor cell frequency or are particularly sensitive to a specific cytokine or cell type missing in the particular xenotransplantation model\[[@B14]\]. For example, AML samples with a t(8;21) translocation were shown to be difficult to be engrafted and found to be dependent on signaling though the TPO/mpl pathway\[[@B82],[@B83]\]. Subsequently, human TPO knock-in mice were shown to have improved engraftment for t(8;21) AML samples\[[@B84]\].

Cell of origin of LSCs
----------------------

It is important to distinguish the concept of the cell of origin from the CSC\[[@B10]\]. The CSC has stem cell like properties and is capable of initiating and sustaining tumor growth, whereas the cell of origin refers to the normal cell in which the initial transforming event occurs. Importantly, cancer and LSCs do not have to arise from a normal stem cell, in fact, it is not entirely clear what the cell of origin for most LSCs is\[[@B11],[@B12]\]. One hypothesis is that LSCs are only able to arise from normal HSCs but not from committed progenitor cells\[[@B10],[@B15]\]. This theory is supported by the observation that LSCs and HSCs share many characteristics like self-renewal capacity controlled by genes like *Bmi1* and *PTEN* and quiescence\[[@B35],[@B85],[@B86]\]. On the contrary, transformation might occur in a variety of cell types in the hematopoietic hierarchy, including HSCs and committed progenitors\[[@B10],[@B87]\]. Experimental evidence in mice shows that LSCs may arise either through neoplastic changes initiated in normal self-renewing HSCs or downstream progenitors cells\[[@B10],[@B11],[@B88]\]. Some oncogenes including *MOZ-TIF*, *MLL-AF9* and *MLL-ENL* can induce LSCs regardless of what target cell population they are expressed in\[[@B88]-[@B90]\]. Other oncogenes like *BCR-ABL*, *FLT3-ITD*, *Hoxa9* and *Meis1* were found to be oncogenic when expressed in HSCs but not when expressed in progenitor cells\[[@B39],[@B89],[@B91]\]. However, experimental data in murine studies might be confounded by non-physiologic levels of expression from exogenous promoters, such as transgenes or retroviral vectors\[[@B11]\]. This was demonstrated by the recent finding that in an MLL-AF9 knock-in model of the same construct shown to initiate disease in both HSCs and progenitor cells by retroviral expression only initiated leukemia from HSCs when expressed from the endogenous MLL promoter\[[@B92]\]. *In vivo* clonality studies in humans suggest variations in the cells of origin and is was demonstrated that in patients with t(8;21) AML primitive CD34^+^CD90^-^CD38^-^ HSC like cells from leukemic bone marrow give rise to normally differentiating progenitors, whereas more mature CD34^+^CD90^-^CD38^+^ multi-potent progenitor like cells form exclusively leukemic blast colonies\[[@B93]-[@B95]\]. These observations suggest that the truth about the cell of origin might be reflected by a combination of both theories depicted above: Although the initial genetic mutation might happen in HSCs subsequent events occur in the committed progenitor pool, giving rise to LSCs\[[@B11]\].

IMPACT OF LSC ON CURRENT TREATMENT AND PROGNOSIS
================================================

Impact on prognosis
-------------------

The LSC burden of AML patient is suggested to be a strong biomarker for clinical outcome in AML\[[@B96]-[@B100]\]. The ability of cells from AML patients to engraft NOD/SCID mice and the LSC frequency (simplistically characterized as CD34^+^CD38^-^ frequency) are associated with worse clinical outcomes\[[@B99]-[@B101]\]. AML patients with greater than 3.5% of CD34^+^CD38^-^ AML cells show a median relapse free survival of 5.6 mo *vs* 16 mo in those with a lower percentage of CD34^+^CD38^-^ cells\[[@B96]\]. Furthermore, poor clinical outcome seems to correlate with the degree to which the LSCs matched normal HSC gene expression\[[@B98]\].

It is noted that it is controversial whether the simplistically phenotypically defined LSC frequency (characterized as CD34^+^CD38**^-^**) in AML is prognostic and correlates with xenograft potential\[[@B14]\]. Also, as described above, LSCs can be found outside of the CD34^+^CD38^-^ cell fraction. An improved characterization of subpopulations of LSCs is expected to be associated with improved prediction of prognosis.

Impact on current therapies
---------------------------

It is thought that LSCs have a significant role in the relapse of leukemia as induction chemotherapy targets the bulk of blast cells but not LSC\[[@B102]\]. Minimal residual disease (MRD) is an important determinant for relapse and poor outcomes in AML and it is likely that the MRD cell population contains LSCs\[[@B103]-[@B105]\]. Thus, in order to improve outcomes in AML, MRD needs to be reduced to prevent disease relapse. LSCs seem to be only minimally affected by traditional chemotherapy\[[@B35],[@B106]\]. Several reasons for chemotherapy resistance have been proposed, which are related to the key features of LSCs discussed above. LSCs are quiescent in the G0 phase of the cell cycle but chemotherapy is only effective in killing rapidly cycling cells\[[@B36],[@B37]\]. LSCs are supported by a stem cell niche in the bone marrow protecting them from the effect of classical chemotherapy\[[@B65]\]. Furthermore, LSCs express high levels of ATP transporters, which are involved in extrusion of chemotherapeutic drugs from LSCs\[[@B107]-[@B109]\].

To improve survival in AML, traditional chemotherapy targeting the blast population needs to be combined with therapy specifically targeting LSCs to maintain prolonged remission.

FUTURE DIRECTIONS FOR THERAPY
=============================

Despite the recent increased interest in LSCs, experimental studies have not been translated into improved survival outcomes for cancer patients. However, several new agents targeting LSC specific surface molecules and pathways as well as the LSC microenvironment remains under different stages of preclinical and clinical development (Table [2](#T2){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). To rationally design clinical trials testing drugs for efficacy against LSCs, it is important to appreciate the fundamental differences between drug design targeting blast cells and LSCs\[[@B102]\]. Principles and challenges faced by targeting LSCs will be discussed first followed by an overview of various new therapeutic options targeting LSCs.

###### 

Emerging therapy targeting leukemia stem cells

  **Drug**                                            **Mechanism**                                                                                                            **Selected clinical trials**                                                                                                                                                                      **Phase**     **Ref**.
  --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- --------------------------
  Therapy targeting cell surface markers                                                                                                                                                                                                                                                                                                                                                       
  GO                                                  Anti-CD33 monoclonal antibody conjugated with calicheamicin, a potent antitumor anthracycline antibiotic                 NCT00882102 NCT01869803 NCT00968071 NCT01409161 NCT00766116 NCT02724163 NCT00658814 NCT02473146 NCT00895934 NCT00006265 NCT00860639 NCT00927498 NCT00085709 NCT00195000 NCT00893399 NCT00017589   Phase I-III   \[124,126, 130,132,133\]
  Hu5F9-G4                                            Anti-CD47 monoclonal antibody                                                                                            NCT02678338                                                                                                                                                                                       Phase I       \[74,141\]
  CSL360                                              Anti-CD123 monoclonal antibody                                                                                           NCT00401739                                                                                                                                                                                       Phase I       \[69,134\]
  DT388IL3/ SL-401                                    Anti-CD123 recombinant immunotoxin created by the fusion of diphtheria toxin with a ligand targeting the IL-3 receptor   NCT02113982 NCT00397579                                                                                                                                                                           Phase I-II    \[69,134,136\]
  MGD006/ S80880                                      Anti-CD3 and CD123 DART                                                                                                  NCT02152956                                                                                                                                                                                       Phase I       \[137\]
  H90                                                 Anti-CD44 monoclonal antibody                                                                                            N/A                                                                                                                                                                                               N/A           \[75,139\]
  A3D8                                                anti-CD44 monoclonal antibody                                                                                            N/A                                                                                                                                                                                               N/A           \[139\]
  Therapy targeting LSC-specific molecular pathways                                                                                                                                                                                                                                                                                                                                            
  Bortezomib                                          Proteasome inhibitor inhibits the degradation of the IkBa creating an anti-NF-κB effect                                  NCT00789256 NCT00382954 NCT01127009 NCT00666588 NCT00703300 NCT01534260 NCT00383474                                                                                                               Phase I-III   \[36,143-147, 175-177\]
  Parthenolide                                        Inhibitor of NF-κB                                                                                                       N/A                                                                                                                                                                                               N/A           \[149\]
  Celastrol                                           Inhibitor of Hsp90 and by extension NF-κB                                                                                N/A                                                                                                                                                                                               N/A           \[150\]
  4-hydroxy- 2-nonenal                                Product of lipid peroxidation, inhibiting the proteasome and NF-κB function                                              N/A                                                                                                                                                                                               N/A           \[151,152\]
  BKM120 CAL-101                                      PI3K inhibitors                                                                                                          NCT01396499 NCT01833169 NCT00710528                                                                                                                                                               Phase I-II    \[38,153,154\]
  GSK21110183 MK-2206 Perifosine                      AKT inhibitors                                                                                                           NCT00881946 NCT01253447 NCT01231919 NCT00301938                                                                                                                                                   Phase I-II    \[38,155-157\]
  Sirolimus, everolimus, temsirolimus                 mTOR inhibitors                                                                                                          NCT01184898 NCT01611116 NCT01074086 NCT01074086 NCT01154439 NCT00775593 NCT02583893 NCT01869114 NCT01822015                                                                                       Phase I-II    \[38,158\]
  Oblimersen (Genasense, G3139)                       bcl-2 antisense oligodeoxynucleotide                                                                                     NCT00085124 NCT00039117 NCT00017589                                                                                                                                                               Phase I-III   \[46,159,160\]
  Obatoclax Mesylate (GX15-070MS)                     Small molecule bcl-2 inhibitor                                                                                           NCT00438178 NCT00684918 NCT00684918                                                                                                                                                               Phase I-II    \[161-163\]
  Therapy targeting the LSC microenvironment                                                                                                                                                                                                                                                                                                                                                   
  G-CSF                                               Mobilization of LSC from the protective bone marrow niche - \> increased susceptibility to traditional chemotherapy      NCT00820976 NCT00602225 NCT00199147 NCT01723657 NCT01101880 NCT00943943 NCT00906945                                                                                                               Phase I-III   \[165-168\]
  Plerixafor (AMD3100)                                CXCR4 inhibitor Decreased homing to the bone marrow                                                                      NCT00943943 NCT00906945 NCT01236144 NCT00512252 NCT01319864 NCT01352650 NCT02416908                                                                                                               Phase I-II    \[61,135,178\]
  AMD3465                                             CXCR4 inhibitor Decreased homing to the bone marrow                                                                      N/A                                                                                                                                                                                               N/A           \[61,135,169,179\]
  BMS-936564                                          Anti-CXCR4 antibody Decreased homing to the bone marrow                                                                  NCT01120457                                                                                                                                                                                       Phase I       \[172\]
  Natalizumab                                         Anti-VLA4 antibody Decreased homing to the bone marrow                                                                   N/A                                                                                                                                                                                               N/A           \[174\]

GO: Gemtuzumab ozogamicin; DART: Dual-affinity retargeting molecule; N/A: Not available; LSC: Leukemia stem cell; IkBa: Inhibitor of kappa B alpha; CXCR4: C-X-C chemokine receptor type 4; mTOR: Mechanistic target of rapamycin; G-CSF: Granulocyte-colony stimulating factor.

General principles and challenges faced by targeting LSCs
---------------------------------------------------------

**Limiting side effects:** As LSCs and HSCs have many similar properties (see above), therapeutic approaches targeting LSCs also have the potential of causing severe side effects by eliminating healthy HSCs. To develop novel therapies with limited side effects, unique properties of LSCs have to be identified\[[@B102],[@B110]\]. While expression of several surface markers is similar between normal HSCs and LSCs (CD34, CD38, CD71 and HLA-DR), other surface antigens are only displayed on LSCs (CD33, CD90, CD117 and CD123)\[[@B110]\]. Apart from a similar immunophenotype, HSCs and LSCs share many pathways important for maintaining features of "stemness" like quiescence and self-renewal capacity\[[@B111]\]. Pathways, which are up-regulated in LSCs compared to normal HSCs, are the ideal target for therapeutic approaches directed towards LSCs. For example, the active form of NF-κB and bcl-2, which are associated with anti-apoptotic activity in cancer cells, are overexpressed in LSCs compared to normal HSC and drugs targeting both NF-κB and bcl-2 are in clinical development\[[@B36],[@B46],[@B112]\].

**Using biomarkers for LSC eradication:** To assess the efficacy of investigational therapies targeting LSCs, precise diagnostic methods are needed to assess the quantity of LSCs present in leukemia patients. Unfortunately, current characterization of LSC phenotype is not precise enough to permit real-time tracking of LSCs *in vivo*\[[@B113]\]. As discussed above, current strategies for purification do not yield functionally homogeneous population: The frequency of LSCs within the CD34^+^CD38^-^ fraction in AML ranges from 1 in 10^4^ to 1 in 5 × 10^6^ cells and several other populations contain LSCs as well\[[@B15]\]. Functional assessment of LSC frequency with xenotransplantation models offers a more robust method to evaluate eradication of LSCs but might not be feasible in large clinical trials\[[@B102]\]. Similarly, methods for detecting MRD might guide decisions by detecting patients who do require additional therapy to prevent relapse. However, detecting MRD does not distinguish persistent LSCs, which may cause relapse, from residual blasts and normal HSCs that do not have tumor-initiating activity. Distinguishing residual LSCs from residual blasts might be accomplished by gene expression analysis showing reactivation of self-renewal genes in LSCs but not in blast cells\[[@B88],[@B114]\]. In preclinical development, the recently published Connectivity Map could be investigated for agents that attenuate a stem cell gene signature or induce a differentiated state\[[@B115],[@B116]\].

**Timing of LSC targeted therapy:** Therapy targeting LSCs is effective in eradicating a small amount of leukemia initiating cells but not the bulk of blasts cells in the blood and bone marrow\[[@B102]\]. By combining drugs eradicating LSCs with standard chemotherapy targeting the bulk of the disease, both the aggressive proliferating process as well as the root of the leukemia can be targeted\[[@B117]\]. An example serves the successful combination of the anti-CD33 immunoconjugate antibody gemtuzumab ozogamicin (GO) with standard chemotherapy\[[@B118]\]. This is associated with challenges in a meaningful design of clinical trials in terms of the correct timing of these therapies. LSC targeting therapy can either be given after reduction of the bulk population with standard chemotherapy as remission therapy or concomitant with chemotherapy as an induction regimen\[[@B102]\]. Upfront combination would allow assessing for additive and/or synergistic properties between drugs and would allow targeting of LSCs early on in the disease process, which might improve outcomes\[[@B102]\]. On the other hand, LSC targeted therapy might be particular valuable as post-consolidation therapy as no current post-consolidation intervention has led to improved OS for patients with AML\[[@B102],[@B119],[@B120]\]. LSC targeting therapies have the potential to fill the gap as they eradicate the cells responsible for relapses of AML.

**Assessing clinical endpoints:** Classical response criteria like CR and hematologic improvement might not be the best parameters to assess the efficacy of therapeutic approaches targeting LSCs as these drugs do not eradicate the bulk of blast cells but rather eliminate the rare population of LSCs\[[@B102]\]. Progression-free survival (PFS), event free survival and overall survival (OS) may be a more relevant endpoint for assessing the effectiveness of LSC elimination than tumor response as they better account for whether the root of the leukemia has been eliminated\[[@B113]\]. Importantly, while LSC frequency was found to be prognostic for survival, response rates did not correlate with LSC burden\[[@B96]\]. Subsequently, drugs targeting LSCs may show little activity if tested in traditional phase I/II trials as a proper assessment of endpoints relevant for LSCs, like PFS and OS, is generally only feasible in a phase III trial with a larger numbers of patients and long-term follow-up\[[@B113],[@B121]\].

One example for the importance of assessing relevant endpoints for LSC targeting therapy, is inconsistency of clinical trials evaluating the efficacy of GO\[[@B102]\]. Single agent studies of GO showed overall response rates only approaching 30% at best and GO was voluntarily withdrawn from the United States market in 2010 after a study showed no improvements in outcomes when used in combination therapy as well as increased fatal toxicity\[[@B122]-[@B124]\]. In contrast, other large clinical trials showed improvement in outcomes more relevant for therapies targeting LSC- event-free survival, disease-free survival and OS- despite no differences in disease response rates\[[@B125]-[@B128]\].

Targeting LSC surface molecules
-------------------------------

**Anti-CD33 antibodies**: CD33 is found on LSCs although it is not a consistent feature of all LSCs studied\[[@B73],[@B118],[@B129]\]. As discussed above, there have been conflicting reports surrounding the efficacy and safety of GO and currently GO is not available on the market in the United States or Europe\[[@B130]\]. Apart from the different endpoints studied, there are additional explanations for the discrepancies observed: First, the dose of daunorubicin as the combination partner of GO did vary between trials, although it is known that treatment with daunorubicin-based schedules of 90 mg/m^2^ for 3 d is more effective than similar schedules with daunorubicin at 45 mg/m^2\[131\]^. In the SWOG trial, which questioned the efficacy of GO, single bolus combined with daunorubicin at 45 mg/m^2^ was studied against a control group with daunorubicin at 60 mg/m^2\[124\]^. However, the best effect of GO was seen when higher dose of GO (3 d at 3 mg/m^2^ for 2 cycles) was added to a daunorubicin regimen of 60 mg/m^2^ in both comparator groups\[[@B126]\]. Furthermore, GO seems to be quite active in acute promyelocytic leukemia (APL) as APL cells express high levels of CD33\[[@B132],[@B133]\]. These results have prompted calls to reconsider the approval status of GO\[[@B130]\].

**Anti-IL-3 receptor (CD123) antibodies:** The interleukin-3 receptor alpha chain (IL-3Rα or CD123) is strongly expressed in CD34^+^/CD38^-^ LSCs and can be targeted with monoclonal antibodies\[[@B69],[@B134]\]. The blockage of CD123 has pleiotropic anti-leukemic effects including inhibition of LSC homing to the bone marrow, activation of innate immunity and inhibition of intracellular signaling events\[[@B135]\]. Several different agents targeting CD123 are currently evaluated in clinical trials: CD123 targeting antibodies can either be naked antibodies or be conjugated to toxins (*e.g*., diphteriod toxin) or chemotherapeutic agents (chemo-immune conjugates) or be the backbone of a bi-specific T cell engager (BITE, *e.g*., CD3-CD123)\[[@B134],[@B136],[@B137]\] (Table [2](#T2){ref-type="table"}).

**Anti-CD44 antibodies:** CD44 regulates interaction between LSCs and the bone marrow niche by controlling cell-cell adhesion and cell-matrix interaction through binding to hyaluronic acid, osteopontin, collagens and others\[[@B138]\].

Inhibition of CD44 with monoclonal antibodies was shown to reduce the numbers of LSCs in NOD/SCID mice and to increase the survival of the primary recipient mice as well prevent engraftment into the secondary receipt mice\[[@B75],[@B139]\] (Table [2](#T2){ref-type="table"}).

**Anti-CD47 antibodies:** CD47 is overexpressed on LSCs and high expression of CD47 is associated with worse outcomes\[[@B74]\]. By interaction with the extracellular region of signal-regulatory protein alpha (SIRPα) on phagocytic cells, LSCs deliver a "do not eat me" message to these phagocytic cells\[[@B140]\]. Antibodies blocking the interaction between CD47 and SIRPα promote LSC phagocytosis and are in development (Table [2](#T2){ref-type="table"})\[[@B74],[@B141]\].

***Targeting LSC-specific molecular pathw*ays**

**NF-**κ**B signaling pathway**: Bortezomib is able to suppress the NF-κB signaling pathway by inhibiting the destruction of IκB, a cellular inhibitory protein of NFκB, by the ubiquitin-proteasome pathway\[[@B142]\]. Several clinical trials are examining the efficacy of Bortezomib targeting AML LSCs (Table [2](#T2){ref-type="table"}): Two clinical trials combining Bortezomib with Cytarabine and Anthracyclines resulted in CR rates of 61% and 65%\[[@B143],[@B144]\], whereas other trials that co-administrated Bortezomib with other drugs did not show encouraging CR rates\[[@B145]-[@B147]\]. Several other inhibitors of NF-κB signaling are in different phases of development (Table [2](#T2){ref-type="table"})\[[@B148]-[@B152]\].

**PI3K/AKT/mTOR pathway**: The PI3K/AKT/mTOR pathway is of utmost importance in regulating cellular growth, survival, and metabolism and is frequently dysregulated in cancers and AML\[[@B38]\]. A multitude of PI3K inhibitors\[[@B153],[@B154]\], AKT inhibitors\[[@B155]-[@B157]\] and mTOR inhibitors\[[@B158]\] is currently investigated for their efficacy targeting LSCs in clinical trials (Table [2](#T2){ref-type="table"}).

**Bcl-2 pathway:** LSCs, similar to other tumor cells, are able to avoid apoptosis due to overexpression of bcl-2\[[@B46]\]. Currently, bcl-2 inhibition is investigated in clinical trials in form of the bcl-2 antisense oligodeoxynucleotide oblimersen\[[@B159],[@B160]\] and the small molecule inhibitor of bcl-2 obatoclax\[[@B161]-[@B163]\] (Table [2](#T2){ref-type="table"}).

Targeting the LSC microenvironment
----------------------------------

Approaches targeting the interactions of LSCs with the bone marrow niche focus on breaking the dormancy of LSCs in the bone marrow in order to make them sensitive to traditional chemotherapy\[[@B62],[@B164]\].

**LSC mobilization**: LSC mobilization from the marrow niche can be achieved by nonspecific stimulators like G-CSF, Interferon-α and Arsenic trioxide\[[@B62]\]. Using the NOD/SCID/IL2rgamma (null) mouse model, Saito et al\[[@B165]\] showed that quiescent human AML LSCs, at first resistant to cytarabine, start proliferating and become susceptible to cytarabine once exposed to G-CSF. Combining chemotherapy with G-CSF leads to significantly increased survival of secondary recipients after transplantation of leukemia cells compared with chemotherapy alone. Furthermore, they showed that treatment with G-CSF before cytarabine did not increase apoptosis of normal HSCs making this approach a particular attractive option for targeting LSCs but at the same time avoiding side effects from depletion of HSCs. The data from clinic trials using G-CSF priming in combination with chemotherapy are conflicting. Löwenberg et al\[[@B166]\] randomized 640 newly diagnosed AML patients to receive cytarabine plus idarubicin with G-CSF (321 patients) or without G-CSF (319 patients) for the first cycle of induction of chemotherapy. Patients in CR after induction chemotherapy plus G-CSF had a higher rate of disease-free survival than patients who did not receive G-CSF (42% *vs* 33% at four years, *P* = 0.02), owing to a reduced probability of relapse (relative risk, 0.77; *P* = 0.04). Other studies did not show a benefit of adding G-CSF to traditional chemotherapy regimens\[[@B167],[@B168]\]. These different responses to G-CSF might be explained by differences in the group of patients included in these trials\[[@B63]\]. In the trial by Löwenberg et al\[[@B166]\] patients with standard-risk AML benefited from G-CSF therapy whereas G-CSF did not improve the outcome in the subgroup with an unfavorable prognosis. In the trials without improvement with G-CSF, patients had a more unfavorable prognosis based on age, cytogenetic abnormalities or response to previous treatment. Several clinical trials are ongoing to investigate the efficacy of G-CSF in combination of chemotherapy in different risk groups of AML (Table [2](#T2){ref-type="table"}).

**Inhibition of homing:** LSC dormancy can be targeted by specifically interrupting the CXCR4-CXCL12 and VCAM-VLA4 axis as well as inhibiting CD44 and CD123 on LSCs to prevent homing of LSCs to the bone marrow.

**CXCR4-CXCL12 axis:** SDF-1 was shown to promote survival of AML cells, whereas addition of neutralizing CXCR4 antibodies, SDF-1 antibodies, or AMD3100 significantly decreased their survival\[[@B169]\]. Furthermore, pretreatment of primary human AML cells with neutralizing CXCR4 antibodies blocked their homing into the BM and spleen of transplanted NOD/SCID/B2m^null^ mice\[[@B169]\]. Additionally, CXCR4 inhibition with AMD3465 was shown to increase the sensitivity of FLT3-mutated leukemic cells to the apoptogenic effects of the FLT3 inhibitor sorafenib\[[@B170]\]. Recently a phase 1/2 study examined the efficacy of the CXCR4 inhibitor plerixafor in combination with mitoxantrone, etoposide, and cytarabine in 52 patients with relapsed or refractory AML\[[@B171]\]. Overall CR was found to be 46% and correlative studies demonstrated a 2-fold mobilization in leukemic blasts into the peripheral circulation without evidence of symptomatic hyperleukocytosis or delayed count recovery. BMS-936564, a fully human IgG4 monoclonal antibody against CXCR4, exhibits antitumor activity in cytarabine-resistant mouse xenograft models of AML and is currently tested in a phase I clinic trial (Table [2](#T2){ref-type="table"})\[[@B172]\].

**VCAM-VLA4 axis:** Integrin alpha4beta1 (VLA4) mediates adhesion of LSCs to stromal cells and extracellular matrix in the marrow niche and can be blocked by the monoclonal antibody Natalizumab\[[@B59],[@B69],[@B173]\]. AML cells were shown to de-adhere from a layer of immobilized human VCAM1 expressing human stromal cells when exposed to Natalizumab and NSG mice transplanted with human AML cells survived significantly longer when they received intraperitoneal Natalizumab injections\[[@B174]\].

CONCLUSION
==========

AML remains one of the most difficult malignancies to treat. Despite significant advancements in the understanding of disease biology, this has not been translated yet into new treatment modalities improving outcomes. The relapse of AML is frequent and is responsible for the inability to cure AML. LSCs are understood to be the root of relapse and their presence has been found to be prognostic for the disease course. Unfortunately, LSCs are not easy to target as they are quiescent, able to self-renew and well protected by a supportive bone marrow niche. Furthermore, their inconsistent phenotype and similarity to normal HSCs hamper specific drug development. Nevertheless, a multitude of potential targets have been identified and are currently tested in different phases of clinical and preclinical development. Successful eradication of LSCs will require combination of different strategies including targeting LSC specific surface molecules and pathways as well as interactions of LSCs with the microenvironment. Furthermore, clinical trials have to be designed in a way that they are able to detect a specific effect of LSCs, which is easy to miss in a traditional trial design. Overall, targeting LSCs has the promise to not only effectively reduce disease burden but to eradicate the root of leukemia itself.
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